Ariad Stock Hits New 52-Week High (ARIA)

NEW YORK (TheStreet) -- Ariad Pharmaceuticals (Nasdaq:ARIA) hit a new 52-week high Friday as it is currently trading at $18.70, above its previous 52-week high of $18.39 with 1.4 million shares traded as of 1:15 p.m. ET. Average volume has been 3.1 million shares over the past 30 days.

Ariad has a market cap of $2.91 billion and is part of the health care sector and drugs industry. Shares are up 45.4% year to date as of the close of trading on Thursday.

ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients.

• ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

TheStreet Ratings rates Ariad as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. You can view the full Ariad Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

For more information on Ariad Pharmaceuticals click any of the following:

• Ariad Pharmaceuticals Stock Price

• Ariad Pharmaceuticals Analyst Ratings

• Ariad Pharmaceuticals Key Stats & Profile

• Ariad Pharmaceuticals Earnings

• Ariad Pharmaceuticals Ratio Comparison

• Ariad Pharmaceuticals Growth Rates

• Ariad Pharmaceuticals Balance Sheet

• Ariad Pharmaceuticals Cash Flow

• Ariad Pharmaceuticals Income Statement